A new study has found a link between high levels of air pollution at an individual’s home address and an elevated risk of developing cardiovascular disease.
Air pollution exposure appears to heighten the production of inflammatory cells in the bone marrow, triggering inflammation of the arteries.
These findings implicate air pollution exposure as an underrecognized risk factor for cardiovascular disease and suggest therapeutic targets beyond pollution mitigation to lessen the cardiovascular impact of air pollution exposure.
Shady Abohashem, MD Massachusetts General Hospital
BOSTON – Tiny particles of air pollution — called fine particulate matter — can have a range of effects on health, and exposure to high levels is a known risk factor for cardiovascular disease. New research led by investigators at Massachusetts General Hospital (MGH) reveals that fine particulate matter has a detrimental impact on cardiovascular health by activating the production of inflammatory cells in the bone marrow, ultimately leading to inflammation of the arteries. The findings are published in the European Heart Journal.
The retrospective study included 503 patients without cardiovascular disease or cancer who had undergone imaging tests at MGH for various medical reasons. The scientists estimated participants’ annual average fine particulate matter levels using data obtained from the U.S. Environment Protection Agency’s air quality monitors located closest to each participant’s residential address.
Over a median follow-up of 4.1 years, 40 individuals experienced major cardiovascular events, such as heart attacks and strokes, with the highest risk seen in participants with higher levels of fine particulate matter at their home address. Their risk was elevated even after accounting for cardiovascular risk factors, socioeconomic factors, and other key confounders. Imaging tests assessing the state of internal organs and tissues showed that these participants also had higher bone marrow activity, indicating a heightened production of inflammatory cells (a process called leukopoiesis), and elevated inflammation of the arteries. Additional analyses revealed that leukopoiesis in response to air pollution exposure is a trigger that causes arterial inflammation.
“The pathway linking air pollution exposure to cardiovascular events through higher bone marrow activity and arterial inflammation accounted for 29% of the relationship between air pollution and cardiovascular disease events,” says co–first author Shady Abohashem, MD, a cardiovascular imaging fellow at MGH. “These findings implicate air pollution exposure as an underrecognized risk factor for cardiovascular disease and suggest therapeutic targets beyond pollution mitigation to lessen the cardiovascular impact of air pollution exposure.”
Co–first author Michael Osborne, MD, a cardiologist at MGH, explains that therapies targeting increased inflammation following exposure to fine particulate matter may benefit patients who cannot avoid air pollution. “Importantly, most of the population studied had air pollution exposures well below the unhealthy thresholds established by the World Health Organization, suggesting that no level of air pollution can truly be considered safe,” he says. This work was supported by the National Institutes of Health.
About the Massachusetts General Hospital Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale description of its risk factors.
Researchers from Mass General Brigham Cancer Institute will present research discoveries and outcomes from clinical trials in hematology/oncology, including cancer and common blood disorders, at the 2025 American Society of Hematology (ASH) annual meeting, held December 6–9, in Orlando.
A study led by Mass General Brigham researchers found that engasertib lessened bleeding events for patients with HHT, the second most common inherited bleeding disorder.
The Sean M. Healey & AMG Center for ALS at Mass General Brigham has selected Tiziana Life Sciences as one of the companies to enter the Healey ALS MyMatch Program. Learn more.
Mass General Brigham study of more than 11,000 adolescents and young adults found those who took buprenorphine for 12 months had almost half the risk of overdose compared to those who discontinued early.
In a study of nearly 30,000 female nurses under age 50, Mass General Brigham researchers found that a high intake of ultra-processed foods was associated with increased risk of adenomas, colon polyps which can be precursors of colorectal cancer.